October 8, 2026 4:00pm EDT XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout
September 18, 2026 8:05am EDT XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity